Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy sit down with our community to share their progress and answer your questions.
The Avidity Biosciences team presents, "MARINA Data: A Preliminary Assessment from the Phase 1/2 Clinical Trial for DM1" on December 16, 2022. Click here to read their recent press release and open letter to the DM Community.
- Kelly DiTrapani, RN, BSN, BA
Avidity Biosciences, Vice President of Medical Affairs
- Nicholas Johnson, MD, MSCI, FAAN
Virginia Commonwealth University, MARINA Principal Investigator
- Mike Flanagan, PhD
Avidity Biosciences, Chief Technical Officer